CARLSBAD, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the formation of an inflammatory disease Scientific Advisory Board (SAB). The SAB will provide independent scientific advice and counsel to the Company regarding key decisions relating to the research and development of drugs to treat chronic inflammatory diseases, such as gout and rheumatoid arthritis.
"We have brought together a group of international authorities in gout and arthritis to form the core of our inflammatory disease SAB," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "These experts will play an integral role in guiding our inflammatory product development strategies."
Mark C. Genovese, M.D., is an Associate Professor of Medicine and Co-Chief of the Division of Immunology and Rheumatology at Stanford University Medical Center. Dr. Genovese established a clinical research program at Stanford University that is focused on bench-to-bedside translational medicine in autoimmune diseases and has designed and participated in many trials investigating novel therapies and therapeutic strategies for the treatment of autoimmune disease and arthritis. He has served as an editor for the textbook, Primary Care Rheumatology, as an associate editor for Kelley's Essentials of Internal Medicine and as an editor on the 7th edition of Kelley's Textbook of Rheumatology.
Arthur Kavanaugh, M.D., is a Professor of Medicine at the University of
California, San Diego (UCSD) School of Medicine and the Director of the
Center for Innovative Therapy in the UCSD Division of Rheumatology,
Allergy, and Immunology. Dr. Kavanaugh has authored more than 240
scientific publications and book chapters. He is on the e
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved